公开(公告)号：US20240360107A1

公开(公告)日：2024-10-31

申请号：US18687664

申请日：2022-08-30

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： Eli Chapman ,  Christopher Zerio

IPC: C07D405/04 ,  A61K31/4709

CPC classification number: C07D405/04 ,  A61K31/4709

Abstract: The present invention features inhibitors of the eIF4A enzyme. These inhibitors have a novel mechanism for inhibiting the eIF4A enzyme by occupying a binding pocket within the eIF4A RNA-binding groove, thereby perturbing RNA binding, blocking ATP hydrolysis, and, consequently, inhibiting RNA helicase activity. Thus, the compounds of the present invention are RNA-competitive, ATP-uncompetitive elF4A inhibitors that directly bind elF4A and inhibit the protein.

公开(公告)号：US12129218B2

公开(公告)日：2024-10-29

申请号：US17262157

申请日：2019-07-24

Applicant: AUTOTAC INC.

Inventor： Yong Tae Kwon ,  Chang Hoon Ji ,  Srinivasrao Ganipisetti ,  Hee Yeon Kim ,  Su Ran Mun ,  Chan Hoon Jung ,  Eui Jung Jung ,  Ki Woon Sung

IPC: A61K39/395 ,  A23L33/10 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/166 ,  A61K31/192 ,  A61K31/277 ,  A61K31/336 ,  A61K31/355 ,  A61K31/4015 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/428 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/551 ,  A61K31/565 ,  A61K47/54 ,  A61K47/55 ,  A61K47/68 ,  A61P25/28 ,  C07C43/23 ,  C07C47/575 ,  C07C217/58 ,  C07C235/06 ,  C07C237/06 ,  C07C275/24 ,  C07C279/12 ,  C07D303/18

CPC classification number: C07C217/58 ,  A23L33/10 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/166 ,  A61K31/192 ,  A61K31/277 ,  A61K31/336 ,  A61K31/355 ,  A61K31/4015 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/428 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/551 ,  A61K31/565 ,  A61K39/3955 ,  A61K47/54 ,  A61K47/55 ,  A61K47/6803 ,  A61K47/6849 ,  A61P25/28 ,  C07C43/23 ,  C07C47/575 ,  C07C235/06 ,  C07C237/06 ,  C07C275/24 ,  C07C279/12 ,  C07D303/18 ,  C07B2200/07

Abstract: The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins.

公开(公告)号：US12128040B2

公开(公告)日：2024-10-29

申请号：US17254991

申请日：2019-07-11

Applicant: Eli Lilly and Company

Inventor： Jeffrey Daniel Cohen ,  Daniel Jon Sall

IPC: A61K31/4709 ,  A61K9/00 ,  A61P35/00 ,  C07D401/12

CPC classification number: A61K31/4709 ,  A61K9/0053 ,  A61P35/00 ,  C07D401/12

Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.

公开(公告)号：US20240342106A1

公开(公告)日：2024-10-17

申请号：US18292258

申请日：2022-07-27

Applicant: UNIVERSITY OF MIAMI ,  THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES

Inventor： Shanta DHAR ,  Nagesh KOLISHETTI ,  Bapurao SURNAR ,  Madhavan NAIR ,  Anuj SHAH ,  Michal TOBOREK

IPC: A61K9/51 ,  A61K31/122 ,  A61K31/403 ,  A61K31/427 ,  A61K31/435 ,  A61K31/439 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4741 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/5025 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/536 ,  A61K31/5365 ,  A61K31/537 ,  A61K31/551 ,  A61K31/573 ,  A61K31/616 ,  A61K31/635 ,  A61K31/675 ,  A61K31/69 ,  A61K31/7072 ,  A61K38/16 ,  A61K38/18 ,  A61K39/395 ,  A61K47/54 ,  A61P31/18

CPC classification number: A61K9/5153 ,  A61K31/122 ,  A61K31/403 ,  A61K31/427 ,  A61K31/435 ,  A61K31/439 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4741 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/5025 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/536 ,  A61K31/5365 ,  A61K31/537 ,  A61K31/551 ,  A61K31/573 ,  A61K31/616 ,  A61K31/635 ,  A61K31/675 ,  A61K31/69 ,  A61K31/7072 ,  A61K38/16 ,  A61K38/18 ,  A61K39/3955 ,  A61K47/548 ,  A61P31/18

Abstract: The present disclosure relates to nanoparticle compositions and uses thereof for treating or preventing HIV infection.

公开(公告)号：US20240316031A1

公开(公告)日：2024-09-26

申请号：US18578850

申请日：2022-07-22

Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Inventor： Suxia LUO ,  Ning LI ,  Yijie MA ,  Liangyu BIE ,  Jiajun LI

IPC: A61K31/4709 ,  A61K31/282 ,  A61K31/506 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/4709 ,  A61K31/282 ,  A61K31/506 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/545

Abstract: A combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer, comprising an anti-PD-L1 antibody and anlotinib or a pharmaceutically acceptable salt thereof. The combination drug further comprises at least one third therapeutic agent. In addition, the present application further provides a use of a combination drug or a pharmaceutic composition, which comprises an anti-PD-L1 antibody and anlotinib or a pharmaceutically acceptable salt thereof, in preparation of a drug for treatment of gastric carcinoma and/or esophagogastric junction cancer.

公开(公告)号：US20240308994A1

公开(公告)日：2024-09-19

申请号：US18593673

申请日：2024-03-01

Applicant: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS

Inventor： Jung-Mi HAH ,  Hyunwook CHO ,  Jihyun BAEK ,  Hyejin KIM ,  Joonhong JUN

IPC: C07D413/12 ,  A61K31/422 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D261/18 ,  C07D413/14

CPC classification number: C07D413/12 ,  A61K31/422 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D261/18 ,  C07D413/14

Abstract: The present invention relates to an isoxazole derivative or a pharmaceutically acceptable salt thereof, and to a composition comprising said derivative as an active ingredient for preventing or treating diseases associated with CSF-1R. The isoxazole derivative of the present invention inhibits CSF-1R, and therefore can be used as a disease associated with CSF-1R for preventing or treating degenerative brain diseases.

公开(公告)号：US20240307547A1

公开(公告)日：2024-09-19

申请号：US18259868

申请日：2021-12-30

Applicant: Captor Therapeutics S.A.

Inventor： Katarzyna KACZANOWSKA ,  Sylvain COTTENS ,  Roman PLUTA ,  Niall DICKINSON ,  Michal WALCZAK

IPC: A61K47/55 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/573 ,  A61K31/69 ,  A61K39/395 ,  A61K47/54 ,  C07D401/04 ,  C07D471/04 ,  C07D495/04

CPC classification number: A61K47/55 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/573 ,  A61K31/69 ,  A61K39/3955 ,  A61K47/545 ,  C07D401/04 ,  C07D471/04 ,  C07D495/04

Abstract: The present invention discloses novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (I), (IIa)-(IIc), (III) and (IV), below.

公开(公告)号：US20240307430A1

公开(公告)日：2024-09-19

申请号：US18671968

申请日：2024-05-22

Applicant: HEFEI KNATURE BIO-PHARM CO., LTD.

Inventor： Junbo GE ,  Aijun SUN ,  Wei LUO ,  Wei WANG ,  Kanglin WANG ,  Lei WANG ,  Beijian ZHANG ,  Zheng DONG ,  Xinyu WENG ,  Yongchao ZHAO

IPC: A61K31/7084 ,  A61K31/4709 ,  A61P9/00

CPC classification number: A61K31/7084 ,  A61K31/4709 ,  A61P9/00

Abstract: A pharmaceutical composition, including nicotinamide adenine dinucleotide (NAD) and a CD38 inhibitor in a weight ratio of 1-5:5-1, where the CD38 inhibitor is compound 78c. A pharmaceutical preparation including the pharmaceutical composition and an application of the pharmaceutical composition in the prevention and/or treatment of doxorubicin-induced cardiotoxicity are further provided.

公开(公告)号：US20240307368A1

公开(公告)日：2024-09-19

申请号：US18488397

申请日：2023-10-17

Applicant: MELINTA SUBSIDIARY CORP.

Inventor： Danping LI ,  Eric S. BURAK ,  David S. DRESBACK ,  Danielle Beurer LORD

IPC: A61K31/4709 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K31/47 ,  A61K47/18 ,  A61K47/26 ,  A61K47/40 ,  A61K47/69 ,  B82Y5/00

CPC classification number: A61K31/4709 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K31/47 ,  A61K47/183 ,  A61K47/26 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00

Abstract: The present invention relates to antimicrobial compositions and more specifically compositions of quinolone carboxylic acid derivatives. These compositions have improved solubility, stability, and tolerability. These compositions are useful for intravenous administration for treating, preventing, or reducing the risk of infection.

公开(公告)号：US20240300921A1

公开(公告)日：2024-09-12

申请号：US18567275

申请日：2022-06-21

Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

Inventor： Chunming Liu ,  David S Watt

IPC: C07D401/14 ,  A61K31/4709 ,  A61K31/496 ,  A61K45/06 ,  A61P35/00 ,  C07D401/04

CPC classification number: C07D401/14 ,  A61K31/4709 ,  A61K31/496 ,  A61K45/06 ,  A61P35/00 ,  C07D401/04

Abstract: Indole-substituted quinolines (ISQs) are provided which may include a variety of substituted piperidines. Methods for treating cancers, including c-MYC-driven cancers, are described including administering the ISQs to a subject in need thereof. The compounds may be administered in combination with a polo-like kinase-1 (Plk1) inhibitor. The Plk1 and the compound may be administered in synergistically effective amounts.